Principal Financial Group Inc. Decreases Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Principal Financial Group Inc. trimmed its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) by 4.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,977 shares of the biopharmaceutical company’s stock after selling 730 shares during the period. Principal Financial Group Inc.’s holdings in Ultragenyx Pharmaceutical were worth $746,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Seven Eight Capital LP raised its holdings in Ultragenyx Pharmaceutical by 38.2% during the 3rd quarter. Seven Eight Capital LP now owns 19,075 shares of the biopharmaceutical company’s stock valued at $680,000 after buying an additional 5,271 shares during the period. Jacobs Levy Equity Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 23.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 748,278 shares of the biopharmaceutical company’s stock worth $26,676,000 after buying an additional 143,991 shares in the last quarter. Deutsche Bank AG boosted its position in Ultragenyx Pharmaceutical by 6.8% during the third quarter. Deutsche Bank AG now owns 947,732 shares of the biopharmaceutical company’s stock valued at $33,787,000 after purchasing an additional 60,001 shares in the last quarter. Wellington Management Group LLP boosted its position in Ultragenyx Pharmaceutical by 0.4% during the third quarter. Wellington Management Group LLP now owns 5,195,880 shares of the biopharmaceutical company’s stock valued at $185,233,000 after purchasing an additional 18,359 shares in the last quarter. Finally, Hudson Bay Capital Management LP boosted its position in Ultragenyx Pharmaceutical by 46.3% during the third quarter. Hudson Bay Capital Management LP now owns 734,272 shares of the biopharmaceutical company’s stock valued at $26,177,000 after purchasing an additional 232,500 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have weighed in on RARE shares. Canaccord Genuity Group raised their price target on Ultragenyx Pharmaceutical from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Friday, May 31st. The Goldman Sachs Group upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $56.00 to $67.00 in a research note on Thursday, June 6th. Stifel Nicolaus raised their price objective on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. Royal Bank of Canada began coverage on Ultragenyx Pharmaceutical in a research note on Monday, April 22nd. They issued an “outperform” rating and a $77.00 price objective for the company. Finally, Wedbush lifted their price target on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a “neutral” rating in a research report on Friday, May 31st. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of “Moderate Buy” and a consensus target price of $86.71.

Read Our Latest Stock Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $40.88 on Friday. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $54.56. The stock’s 50 day moving average is $40.94 and its two-hundred day moving average is $44.89.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The business had revenue of $108.83 million during the quarter, compared to analyst estimates of $116.03 million. During the same period in the previous year, the business posted ($2.33) earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.46 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.10, for a total value of $71,390.70. Following the sale, the director now directly owns 7,248 shares of the company’s stock, valued at $297,892.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total value of $441,270.00. Following the sale, the executive vice president now directly owns 57,981 shares of the company’s stock, valued at $2,609,145. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.10, for a total value of $71,390.70. Following the completion of the sale, the director now directly owns 7,248 shares in the company, valued at $297,892.80. The disclosure for this sale can be found here. Insiders have sold 12,269 shares of company stock valued at $542,855 over the last ninety days. Insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Profile

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Read More

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.